Castle Biosciences (CSTL) Stock Price, News & Analysis

-0.17 (-0.85%)
(As of 10:28 AM ET)
Today's Range
50-Day Range
52-Week Range
8,392 shs
Average Volume
230,435 shs
Market Capitalization
$545.98 million
P/E Ratio
Dividend Yield
Price Target

Castle Biosciences MarketRank™ Stock Analysis

Analyst Rating
3.00 Rating Score
56.0% Upside
$31.00 Price Target
Short Interest
5.21% of Shares Sold Short
Dividend Strength
News Sentiment
0.89mentions of Castle Biosciences in the last 14 days
Based on 7 Articles This Week
Insider Trading
Selling Shares
$1.05 M Sold Last Quarter
Proj. Earnings Growth
From ($2.41) to ($2.28) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.05 out of 5 stars

Medical Sector

553rd out of 909 stocks

Medical Laboratories Industry

15th out of 20 stocks

CSTL stock logo

About Castle Biosciences Stock (NASDAQ:CSTL)

Castle Biosciences, Inc., a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus. In addition, the company provides DecisionDx-UM test, a proprietary risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma; and IDgenetix, a pharmacogenomic test that helps guide drug treatment for major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, social phobia, obsessive-compulsive personality disorder, post-traumatic stress disorder, and attention deficit hyperactivity disorder. It offers its products to skin cancer, gastroenterology, and mental health markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.

CSTL Stock Price History

CSTL Stock News Headlines

A new way to collect income from stocks
Most people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively…
A new way to collect income from stocks
Most people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively…
CSTL Apr 2024 17.500 call
See More Headlines
Receive CSTL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Castle Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Confirmed)
Fiscal Year End

Industry, Sector and Symbol

Medical laboratories
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
3 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
$219.79 million
Book Value
$14.54 per share


Free Float
Market Cap
$545.98 million
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

CSTL Stock Analysis - Frequently Asked Questions

Should I buy or sell Castle Biosciences stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Castle Biosciences in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CSTL shares.
View CSTL analyst ratings
or view top-rated stocks.

What is Castle Biosciences' stock price target for 2024?

3 brokerages have issued 1 year price targets for Castle Biosciences' stock. Their CSTL share price targets range from $25.00 to $37.00. On average, they expect the company's share price to reach $31.00 in the next twelve months. This suggests a possible upside of 56.0% from the stock's current price.
View analysts price targets for CSTL
or view top-rated stocks among Wall Street analysts.

How have CSTL shares performed in 2024?

Castle Biosciences' stock was trading at $21.58 at the beginning of the year. Since then, CSTL stock has decreased by 7.9% and is now trading at $19.87.
View the best growth stocks for 2024 here

When is Castle Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our CSTL earnings forecast

How can I listen to Castle Biosciences' earnings call?

Castle Biosciences will be holding an earnings conference call on Thursday, May 2nd at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

How were Castle Biosciences' earnings last quarter?

Castle Biosciences, Inc. (NASDAQ:CSTL) announced its quarterly earnings results on Wednesday, February, 28th. The company reported ($0.10) EPS for the quarter, beating analysts' consensus estimates of ($0.84) by $0.74. The company earned $66.12 million during the quarter, compared to analyst estimates of $51.32 million. Castle Biosciences had a negative net margin of 26.15% and a negative trailing twelve-month return on equity of 14.92%.

What guidance has Castle Biosciences issued on next quarter's earnings?

Castle Biosciences issued an update on its FY 2024 earnings guidance on Wednesday, February, 28th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $235.0 million-$240.0 million, compared to the consensus revenue estimate of $214.7 million.

What other stocks do shareholders of Castle Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Castle Biosciences investors own include AbbVie (ABBV), Advanced Micro Devices (AMD), NVIDIA (NVDA), Block (SQ), DexCom (DXCM), QUALCOMM (QCOM), Teladoc Health (TDOC), Applied Materials (AMAT), Incyte (INCY) and Intel (INTC).

When did Castle Biosciences IPO?

Castle Biosciences (CSTL) raised $50 million in an initial public offering (IPO) on Thursday, July 25th 2019. The company issued 3,300,000 shares at a price of $14.00-$16.00 per share. SVB Leerink and Baird acted as the underwriters for the IPO and Canaccord Genuity and BTIG were co-managers.

Who are Castle Biosciences' major shareholders?

Castle Biosciences' stock is owned by many different retail and institutional investors. Top institutional shareholders include Wasatch Advisors LP (9.29%), Norden Group LLC (0.09%), Allspring Global Investments Holdings LLC (0.04%) and Denali Advisors LLC (0.03%). Insiders that own company stock include Adam Jay Sussman, Bernhard E Spiess, Daniel Bradbury, David S Kabakoff, Derek J Maetzold, Derek J Maetzold, Ellen Goldberg, Frank Stokes, Jeffrey E Eberwein, Kristen M Oelschlager, Tiffany Olson and Tobin W Juvenal.
View institutional ownership trends

How do I buy shares of Castle Biosciences?

Shares of CSTL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CSTL) was last updated on 4/24/2024 by Staff

From Our Partners